Introduction
In vitro metabolic clearance (CL int ) derived from liver microsomal incubations is used routinely to aid compound selection in drug discovery. Hepatocytes, which possess intact cellular membranes, complete enzymatic systems and cofactors, have also become a common option for determination of CL int . Successful prediction of in vivo CL from CL int in liver microsomes or hepatocytes has been reported for some compounds. Obach (1999) reported that CL was predicted within a 2-fold error for 16 out of 29 compounds from CL int in human liver microsomes using the well-stirred model incorporating both fu b and fu inc . Similarly, CL int from human hepatocytes provided prediction within a 2-fold error for 11 out of 37 (Brown et al., 2007) or 23 out of 56 compounds (Riley et al., 2005) . However, a tendency towards underprediction was observed for many drugs (Obach, 1999; Ito and Houston, 2004; Riley et al., 2005; Brown et al., 2007; Stringer et al., 2008) . Marked under-prediction of CL from in vitro metabolic CL int in humans and/or animals has been reported for compounds such as montelukast, troglitazone, FK1052, and quinotolast (Naritomi et al., 2001; Riley et al., 2005) .
The reasons for a poor prediction of in vivo CL from in vitro CL int are often not explored in depth. Few reports have systematically examined the reasons for the discrepancy between predicted and observed CL, aside from the possible contribution of renal CL. Factors such as extrahepatic metabolism (De Kanter et al, 2004) , variations in experimental design (Tang et al., 2008) , differences between in vitro and in vivo metabolic enzyme activities, or possible inaccuracy in measurement of plasma unbound fraction (fu p ) for highly bound compounds could potentially contribute to the poor in vitro and in vivo correlation. It is increasingly recognized that drug transporters such as uptake transporters of the organic anion transport polypeptide This article has not been copyedited and formatted. The final version may differ from this version. family and the efflux transporters P-glycoprotein (Pgp) and breast cancer resistance protein (Bcrp) may play a significant role in the elimination of many drugs (Shitara et al., 2006) .
Transporters may even affect the CL of compounds that are eliminated primarily as metabolites, such as repaglinide (Bidstrup et al., 2003; Niemi et al., 2005) and cerivastatin (Shitara et al., 2003) .
During the lead optimization process for one of our internal projects, a lack of correlation was observed between CL int obtained from rat liver microsomes (RLM) and in vivo CL observed in rats. Several additional experiments were conducted to gain a better understanding of the reasons for the poor in vitro and in vivo correlation. Initial results suggested that the correlation was not improved when fresh rat hepatocytes were used to determine CL int . Therefore, the quantitative prediction of rat CL from in vitro metabolic CL int in RLM or rat hepatocyte suspensions was investigated in depth using a set of 41 proprietary compounds. Compound selection was based on in vivo CL, CL int in RLM, and structural diversity within the chemical series. For the majority of the compounds examined, rat CL was significantly under-predicted from CL int obtained from either RLM or rat hepatocytes using the well-stirred model incorporating fu b and fu inc (Ito and Houston, 2004) . Preliminary data indicated that several compounds from the project were substrates for Pgp and Bcrp in vitro; several also displayed low permeability. We hypothesized that transporters might contribute to the lack of correlation between in vitro CL int and in vivo CL in the rat. We report here the examination of the relationship between permeability, efflux, and the predictability of CL. The impact of permeability and efflux on the predictability of human CL was also evaluated using 16 marketed drugs.
This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. in the femoral artery and vein. The rats were housed in a temperature-and humidity-controlled environment subject to a 12 h:12 h light:dark cycle and had access to water and a standard laboratory rodent diet ad libitum. Animals were allowed to acclimate for one week prior to use.
Intravenous Pharmacokinetic Studies in Male Rats
Rats were administered a single dose of test material (0.25 mg/kg) by bolus intravenous injection into the femoral vein catheter and the catheter was flushed with blank vehicle to ensure the full dose was given. Blood samples were collected from the femoral artery catheter at 0.083 (5 min), 0.25, 0.5 1, 2, 4, 6, 8 and 24 h post-dose. Plasma was separated by centrifugation and stored at -80° C. Plasma samples were extracted by the addition of acetonitrile containing 0.1% formic acid and an internal standard. Plasma samples were analyzed using the liquid chromatography tandem mass spectrometry method (LC-MS/MS) system described below.
Isolation of Rat Hepatocytes
Rat hepatocytes were isolated using the two-step collagenase method described by Seglen (1976) , with some modifications. Briefly, the rat was euthanized via CO 2 asphyxiation and the liver was exposed and cannulated within 3 minutes. The vena cava was cannulated caudal to the hepatic vein using PE-60 tubing and the portal vein was bisected. The liver was perfused with calcium This article has not been copyedited and formatted. The final version may differ from this version. free-HBSS supplemented with HEPES, sodium biocarbonate, 1 mM EDTA and 1% BSA until it was cleared of blood. The liver was perfused further with HBSS containing 0.05 % Type IV collagenase and 3 mM calcium chloride until extensive dissociation was evident. The liver was agitated gently to release cells from the capsule into ice-cold phenol free-DMEM supplemented with 10% FBS and 2 mM glutamine. The cells were then filtered through sterile gauze and centrifuged at 50 g for 5 min at 4 °C. The resuspended cells were mixed with equal volume of Percoll in phosphate buffered saline and centrifuged at 200 g for 10 min. The pellet was washed a final time and re-suspended in DMEM supplemented with 2 mM glutamine. The viability was determined using the trypan blue exclusion method and only cells with a viability of greater than 85% were used.
Determination of CL int in RLM and Fresh Rat Hepatocytes
In vitro intrinsic clearances (CL int ) were determined in duplicate using the substrate depletion method (Obach, 1999 The samples were centrifuged at 3500 g for 15 min and the supernatants were analyzed using the LC-MS/MS method described below. For each compound, peak areas at each time point were converted to the natural log of the percent remaining relative to the 0-minute samples (Obach, 1999) . The resulting slope of these values relative to time (k) was converted to in vitro t 1/2 where t 1/2 = -0.693/k. CL int was calculated using the following relationship:
where M is the concentration of microsomes or hepatocytes in the incubation.
For the scaling of rat CL int , values of 40 g liver/kg body weight (Davis and Morris, 1993) , 45 mg microsomal protein/g liver (Naritomi et al., 2001) and 120 x 10 6 hepatocytes/g liver (Naritomi et al., 2003) were assumed.
Determination of Fraction Unbound in Rat Plasma, Liver Microsomes, Hepatocytes, and

Blood-to-plasma Concentration Ratio
Fraction unbound in plasma (fu p ) was determined in triplicate using an ultracentrifugation technique (Nakai et al., 2004) . Plasma was spiked with test compound to achieve a final concentration of 5 µM and was centrifuged at 600,000 g for 3 h at 37 °C. Aliquots of the middle experiments, the hepatocyte reaction mixture described above underwent a freeze-thaw cycle and then was treated with aminobenzotriazole (100 µM) to inhibit metabolism. Microsomal or hepatocyte suspensions were spiked with test compounds to achieve a final concentration of 1 µM and were dialyzed against 1.7 volumes of the corresponding buffer for 5 h at 37 °C.
Preliminary experiments with selected compounds indicated that a 5-h incubation time was sufficient to achieve equilibrium. Aliquots of the dialysate were transferred into an equal volume of blank suspension (microsomes or hepatocytes) and extracted with 2 volumes of acetonitrile. Samples of the dialyzed drug-suspensions were mixed with an equal volume of buffer and extracted with 2 volumes of acetonitrile.
All samples from the binding studies were centrifuged at 3500 g for 15 min and analyzed by LC-MS/MS as described below. The fraction unbound in plasma was calculated using the following relationship: fu p = middle fraction peak area/(2 × spiked plasma peak area). The fraction unbound in liver microsomes or hepatocytes was calculated using the relationship: fu inc = dialysate peak area/dialyzed drug-suspension peak area.
This article has not been copyedited and formatted. The final version may differ from this version. Blood-to-plasma concentration ratio was determined in vitro following incubation of compound with fresh rat whole blood. Blood was warmed to 37°C and test compound was spiked to a concentration of 1 µM. The blood samples were processed for plasma after 1 hour incubation at 37 °C. Reference plasma was also spiked with test compound to a concentration of 1 µM.
Samples were extracted with 6 volumes of acetonitrile containing internal standard, centrifuged and analyzed on the LC-MS/MS system described below. The blood to plasma concentration ratio was calculated by dividing the peak area observed in the reference plasma (representing nominal blood concentration) by the peak area observed in the treated plasma (representing plasma concentration). Papp values for a few compounds; therefore, those compounds were retested in the presence of 0.1% BSA, which tends to improve recovery for many hydrophobic compounds. Transport studies were conducted at 37 °C in a humidified incubator with shaking (70 rpm) for 120 min.
Transport across MDR1-LLC-PK1, mBcrp-MDCK and MDCK cells
MDR1-LLC-
Samples were analyzed by LC-MS/MS as described below.
The apparent permeability (Papp), recovery and efflux ratios were calculated according to the following equations (Polli et al, 2001 ):
where A is the membrane surface area, C 0 is the donor drug concentration at t = 0, dQ/dt is the 
LC-MS/MS Analysis
The LC-MS/MS system consisted of 2 LC-10AD HPLC pumps and a DGU-14A degasser This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Intrinsic Clearance of Proprietary Compounds in RLM and Hepatocyte Suspensions
The compound set displayed a wide range of CL int , from <5 to 865 µL/min/mg in RLM and <5 to 126 µL/min/million cells in hepatocytes (Table 1) . When corrected for the binding of drug to microsomes or hepatocytes, unbound CL int determined from RLM and hepatocytes was comparable for the majority of the compounds (Figure 1 ). However, a significant difference in unbound CL int between RLM and hepatocytes was observed for some compounds. The unbound CL int of compounds 28, 30, 36, 39, and 40 was more than 3-fold higher in hepatocytes than in RLM. In contrast, the unbound CL int of compounds 14, 21, and 37 was more than 3-fold lower in hepatocytes than the very high CL int observed in RLM.
Plasma Protein, Microsomal and Hepatocyte Binding of Proprietary Compounds
In general, the compound set was highly protein bound in rat plasma, with fu p ranging from 0.001 to 0.097 (Table 1) . Overall, hepatocyte and microsomal binding of the compound set were comparable under the experimental conditions (microsomal concentration of 0.25 mg/mL and hepatocyte density of 0.5 million cells/mL) ( Table 1) . Most compounds had fu inc of greater than 0.5, while a few compounds had fu inc of less than 0.5. Compound 41 was highly bound to both microsomes and hepatocytes; the fu inc for this compound was 0.07 in both microsomal and hepatocyte incubations.
Prediction of Rat CL
The in vivo plasma CL of the test compounds ranged from 3 to 7964 mL/hr/kg (Table 1 ). Blood to plasma concentration ratio was determined for a few compounds, and the tested compounds This article has not been copyedited and formatted. The final version may differ from this version. did not distribute into blood cells extensively. Based on this finding, a blood to plasma partition ratio of 1 was assumed for all compounds and, therefore, plasma CL was considered to be equal to blood CL and fu p was assumed to be equal to fu b . For 28 of the 41 compounds examined, CL int derived from RLM under-predicted CL by more than 3-fold, with the under-prediction as great as 541-fold (Figure 2A) . The AFE using RLM data was 7.6. Although CL int from hepatocytes provided better prediction than RLM for some compounds, CL remained underpredicted for the majority. CL was under-predicted by more than 3-fold for 31 compounds, with under-prediction up to 70-fold ( Figure 2B ). The AFE using rat hepatocytes was 7.5.
Passive Permeability and Efflux of the Proprietary Compounds
Passive permeability was estimated from MDCK cells, a cell line commonly used for in vitro permeability tests (Irvine et al., 1999) . Under our experimental conditions, the Papp values for the paracellular marker compound atenolol and the transcellular marker compound propranolol were ≤ 2 and 28.5 × 10 -6 cm/s, respectively. The passive permeability of the test compounds ranged from <3.2 to 46 × 10 -6 cm/s, with the majority displaying passive permeability greater than 5 × 10 -6 cm/s (Table 1) .
Since Pgp species difference in substrate specificity between human and mouse is minimal (Feng el al., 2008) and the ABCG2 gene is highly conserved (Robey et al., 2009) , it was assumed that there was no species difference in Pgp-and Bcrp-mediated transport for the test compounds.
Pgp-mediated transport was evaluated using MDR1-LLC-PK1 cells, which express human Pgp.
Loperamide (1 µM), a known Pgp substrate, exhibited an efflux ratio greater than 20. Bcrpmediated transport was evaluated using mBcrp-MDCK cells, which express mouse Bcrp.
This article has not been copyedited and formatted. The final version may differ from this version. Prazosin, which was used as a control for the Bcrp assay, displayed an efflux ratio greater than 15. Many of the compounds in the set were good substrates for both Pgp and mBcrp. The efflux ratios ranged from 0.6 to 46 in MDR1-LLC-PK1 cells and from 1.1 to 41 in mBcrp-MDCK cells.
Classification and Physicochemical Properties of the Proprietary Compounds
The 41 proprietary compounds were classified into three categories based on passive permeability and efflux ratios in MDR1-LLC-PK1 and mBcrp-MDCK cells. The twelve Type I compounds were characterized by passive permeability values greater than 5 × 10 -6 cm/s and efflux ratios less than 5 in both MDR1-LLC-PK1 and mBcrp-MDCK cells. The twenty Type II compounds displayed passive permeability greater than 5 × 10 -6 cm/s and efflux ratios greater than 5 in either cell line. The remaining nine compounds were categorized as Type III, which had passive permeability values less than 5 × 10 -6 cm/s in MDCK cells and efflux ratios ranging from <1 to 26.6 (Tables 1 and 2 ).
The accuracy in predicting CL from CL int varied significantly among the three classes of compounds. For Type I compounds, in vivo CL ranged from 3 to 2660 mL/hr/kg. In vitro CL int derived from either RLM or hepatocytes predicted in vivo CL reasonably well, with AFEs of 1.8 and 2.3, respectively ( Figure 3A , Table 2 ). The in vivo CL of Type II compounds ranged from 15 to 7600 mL/hr/kg. CL was under-predicted from RLM by more than 3-fold for 15 out of 20
Type II compounds with an AFE of 7.4. A similar degree of under-prediction was observed when hepatocytes data was used to predict CL for this class of compounds ( Figure 3B , Table 2 ).
All Type III compounds exhibited high CL; for the majority, CL exceeded hepatic blood flow Figure 3C , Table 2 ).
Selected physicochemical properties of the 41 proprietary compounds used in the present study are shown in Table 3 . Molecular weight ranged from 337 to 523 mol/g and PSA ranged from 56 to 137. Most compounds were hydrophobic and neutral, while some were basic. Statistically significant differences (P < 0.01) were observed in the physiochemical properties among the three Types (Table 4) . Some physical chemical properties may be correlated to each other. All the compounds that displayed PSA less than 100 contained no hydrogen bond donors, while most of the compounds with PSA greater than 100 contained 1 to 2 hydrogen bond donors. In vitro CL int provided better prediction for compounds with lower PSA and fewer hydrogen bond acceptors and donors (Table 5) .
Permeability, Efflux status, Physical Chemical Properties and Classification of 16
Marketed Drugs
Sixteen marketed drugs which exhibited a wide range of human in vivo clearance (0.3 to 19.2 mL/min/kg) and varying degrees of under-prediction of CL from in vitro metabolic CL int (Obach, 1999; Riley, 2005) were selected for permeability and efflux determinations (Table 6 ). Nine compounds, including buspirone, clozapine, diclofenac and imipramine, displayed high passive permeability and low efflux ratios in both MDR1-LLC-PK1 and mBcrp-MDCK cells that are characteristics of Type I compounds. In vivo clearance of these Type I drugs was well predicted using CL int derived from either human hepatocytes or human liver microsomes. The AFE for these compounds was 1.7. The in vivo CL of bosentan, cyclosporine, montelukast and This article has not been copyedited and formatted. The final version may differ from this version. To investigate potential causes for the under-prediction, we examined the relationship between predictability, passive permeability, and efflux status. Based on the data generated, the 41 compounds were grouped into three categories that exhibited different degrees of underprediction. For Type I compounds, which exhibited good passive permeability and low efflux ratios in both MDR1-LLC-PK1 and mBcrp-MDCK cells, in vivo CL in rats was predicted reasonably well from in vitro CL int. Type II compounds, which displayed good permeability and high efflux ratios in either cell line, showed a wide range of CL. CL was predicted within 3-fold error for only a few compounds; the AFE for compounds in this group was 7 to 8. In contrast to Type I and II compounds, all Type III compounds were poorly permeable (Papp <5 × 10 -6 cm/s) and most displayed CL that exceeded hepatic blood flow. In vitro CL int obtained from RLM dramatically under-predicted in vivo CL for Type III compounds. The magnitude of the underprediction was reduced to some extent when CL int derived from hepatocyte data was used to predict CL; however, none of these compounds' CL was predicted within 3-fold error.
This article has not been copyedited and formatted. The final version may differ from this version. Preliminary data indicated that these Type III compounds were stable in rat plasma and did not distribute extensively into blood cells (data not shown). Plasma instability and partitioning into blood cells, therefore, were unlikely to be the reasons for the under-prediction of CL. Tang et al.
(2008) have suggested that the sampling scheme used in pharmacokinetics studies can have a profound effect on the calculation of in vivo CL. The addition of a 2 min time point was reported to reduce CL by more than 2-fold. The in vivo CL data for our compound set were collected from discovery pharmacokinetic screening studies, in which the first blood sample was collected at 5 min post-dose. Further studies are being conducted to evaluate the potential overestimation of in vivo CL for some compounds in the current set.
Physicochemical properties, such as lipophilicity, hydrogen bonding ability, and polar surface area can affect the permeability and efflux status of a compound (Egan and Lauri, 2002; Malkia et al., 2004; Stouch and Gudmundsson, 2002 The sixteen drugs were also classified into three categories based on permeability and efflux data.
Similar to the proprietary compounds examined, Type I marketed drugs tend to have lower molecular weight, PSA and fewer hydrogen bond acceptors and donors than Type II and III marketed drugs. Despite of the potential impact of inter-laboratory variability of in vitro data on prediction, the trend observed with our internal data in rats appears to be applicable to the human predictions reported in the literature. Consistent with accurate prediction of rat clearance, the human CL for the Type I marketed drugs could be predicted well from in vitro metabolic CL int (Obach, 1999; Riley et al, 2005) . As was observed for the rat, metabolic CL int under-predicted human CL for Type II and III marketed drugs such as bosentan, montelukast and prazosin (Riley et al, 2005) . Our results suggested that the under-prediction of CL for these drugs was due in part to the involvement of transporters in their elimination. Type II compounds were good substrates for Pgp and/or Bcrp, which are expressed not only in the liver, but also in the kidney and intestine (Shitara et al., 2006 (Leusch et al., 2002) . The interplay between transporters and metabolic enzymes could influence the predictability of CL from in vitro metabolic CL int as well. In Caco-2 cells expressing CYP3A4, Pgp inhibition reduces the extent of metabolism of K77, which is a substrate for both CYP3A4 and Pgp. In contrast, the metabolism of felodipine, which is a substrate for CYP3A4 only, is not affected by Pgp inhibition (Cummins et al., 2002) , supporting a role for Pgp in modulating metabolism.
The drastic under-prediction of CL from metabolic CL int for Type III compounds suggested that permeability might have the greatest influence on disposition. Our results were consistent with the trend described by Wu and Benet (2005) that the predominant routes of elimination for poorly permeable compounds were renal and/or biliary excretion of unchanged drug rather than metabolism. Using metabolic CL int in the well-stirred model to predict in vivo CL relies on the This article has not been copyedited and formatted. The final version may differ from this version. assumption that rapid equilibrium between blood and hepatocytes can be reached, an assumption which may be valid only for compounds that exhibit high passive permeability. Poorly permeable compounds may need to utilize uptake and efflux transporters to cross cellular membranes efficiently. Bosentan and montelukast, which are mainly excreted into bile as metabolites in human (Balani et al., 1997; Weber et al., 1999) and displayed poor passive permeability, have been shown to be substrates for uptake transporters (Treiber et al., 2007; Mougey et al., 2009) . Hepatic uptake could be a rate determining step in their elimination.
Further investigation is required into the significance of uptake transporters in the elimination of Type III compounds and the prediction of CL from in vitro data.
In summary, the accuracy of predicting CL from in vitro metabolic CL int could be differentiated by permeability and Pgp-and mBcrp-mediated efflux for the compound set. Clearance could be predicted reasonably well from in vitro metabolic CL int for compounds that displayed high passive permeability (>5 × 10 -6 cm/s) and that were not good substrates (efflux ratio <5) for efflux transporters such as Pgp and mBcrp. For compounds with poor passive permeability (<5 × 10 -6 cm/s) or for compounds that were good Pgp and/or mBcrp substrates (efflux ratio >5) and exhibited high passive permeability, in vitro metabolic CL int was unlikely to be predictive of in vivo CL due to the significant role that transporters might play in their elimination. These data demonstrate that passive permeability and efflux must be taken into consideration when attempting to predict in vivo CL from in vitro CL int and additional models need to be developed.
This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version.
